Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez, Patrick [UCL] Pavelka, Karel Lazaro, Maria Alicia Garcia-Kutzbach, Abraham Moots, Robert J Amital, Howard Govoni, Marinella Vastesaeger, Nathan et al.[show all]

GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria. This analysis included 3280 participants from the GO-MORE trial. All participants included in this analysis had high or moderate disease activity at baseline. At baseline, high disease activity was least common in Europe (71.0%), Canada (77.0%), and the Middle East (78.2%) and most common in Latin America (90.7%), South Africa (91.5%), and Asia (92.5%). Month 6 remission rates were highest in South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Higher rates of remission in each geographical region generally corresponded with lower baseline disease activity. We suspect that access to care and implementation of the treat-to-target strategy were the most important determinants, but this apparent relationship needs to be confirmed in further studies that include a statistical analysis of prognostic indicators.

• metadata
• References
• relations

Document type	Article de périodique (Journal article) – Article de recherche
Access type	Accès libre
Publication date	2018
Language	Anglais
Journal information	"Clinical Rheumatology" - Vol. 37, no.5, p. 1417-1420 (2018)
Peer reviewed	yes
Publisher	Springer ((Germany) Heidelberg )
issn	0770-3198
e-issn	1434-9949
Publication status	Publié
Affiliations	UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales UCL - (SLuc) Service de rhumatologie
MESH Subject	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; Antirheumatic Agents ; Arthritis, Rheumatoid ; Drug Therapy, Combination ; Female ; Humans ; Male ; Methotrexate ; Middle Aged ; Prospective Studies ; Remission Induction ; Severity of Illness Index ; Treatment Outcome ; Young Adult
Keywords	Antirheumatic agents ; Clinical trial ; Geographic locations ; Golimumab ; Rheumatoid arthritis
Links	https://www.ncbi.nlm.nih.gov/pubmed/29611083[Pubmed] https://doi.org/10.1007/s10067-018-4074-6[DOI] http://hdl.handle.net/2078.1/220482[Handle]

1. Smolen J. S., Aletaha D., Bijlsma J. W. J., Breedveld F. C., Boumpas D., Burmester G., Combe B., Cutolo M., de Wit M., Dougados M., Emery P., Gibofsky A., Gomez-Reino J. J., Haraoui B., Kalden J., Keystone E. C., Kvien T. K., McInnes I., Martin-Mola E., Montecucco C., Schoels M., van der Heijde D., , Treating rheumatoid arthritis to target: recommendations of an international task force, 10.1136/ard.2009.123919
2. Smolen Josef S, Landewé Robert, Breedveld Ferdinand C, Buch Maya, Burmester Gerd, Dougados Maxime, Emery Paul, Gaujoux-Viala Cécile, Gossec Laure, Nam Jackie, Ramiro Sofia, Winthrop Kevin, de Wit Maarten, Aletaha Daniel, Betteridge Neil, Bijlsma Johannes W J, Boers Maarten, Buttgereit Frank, Combe Bernard, Cutolo Maurizio, Damjanov Nemanja, Hazes Johanna M W, Kouloumas Marios, Kvien Tore K, Mariette Xavier, Pavelka Karel, van Riel Piet L C M, Rubbert-Roth Andrea, Scholte-Voshaar Marieke, Scott David L, Sokka-Isler Tuulikki, Wong John B, van der Heijde Désirée, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, 10.1136/annrheumdis-2013-204573
3. Emery Paul, Fleischmann Roy, van der Heijde Désirée, Keystone Edward C., Genovese Mark C., Conaghan Philip G., Hsia Elizabeth C., Xu Weichun, Baratelle Anna, Beutler Anna, Rahman Mahboob U., The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy, 10.1002/art.30263
4. Weinblatt Michael E, Bingham Clifton O, Mendelsohn Alan M, Kim Lilianne, Mack Michael, Lu Jiandong, Baker Daniel, Westhovens Rene, Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial, 10.1136/annrheumdis-2012-201411
5. Smolen Josef S, Kay Jonathan, Doyle Mittie K, Landewé Robert, Matteson Eric L, Wollenhaupt Jürgen, Gaylis Norman, Murphy Frederick T, Neal Jeffrey S, Zhou Yiying, Visvanathan Sudha, Hsia Elizabeth C, Rahman Mahboob U, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, 10.1016/s0140-6736(09)60506-7
6. Combe Bernard, Dasgupta Bhaskar, Louw Ingrid, Pal Sarvajeet, Wollenhaupt Jürgen, Zerbini Cristiano A F, Beaulieu Andre D, Schulze-Koops Hendrik, Durez Patrick, Yao Ruji, Vastesaeger Nathan, Weng Haoling H, , Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study, 10.1136/annrheumdis-2013-203229
7. Fransen Jaap, van Riel Piet L.C.M., The Disease Activity Score and the EULAR Response Criteria, 10.1016/j.rdc.2009.10.001
8. Vastesaeger Nathan, Kutzbach Abraham Garcia, Amital Howard, Pavelka Karel, Lazaro María Alicia, Moots Robert J., Wollenhaupt Jürgen, Zerbini Cristiano A. F., Louw Ingrid, Combe Bernard, Beaulieu Andre, Schulze-Koops Hendrik, Dasgupta Bhaskar, Fu Bo, Huyck Susan, Weng Haoling H., Govoni Marinella, Durez Patrick, Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab, 10.1093/rheumatology/kew179
9. Alonso Alberto, González Carlos M., Ballina Javier, García Vivar María L., Gómez-Reino Juan J., Marenco Jose Luis, Fernández-Nebro Antonio, Ordás Carmen, Cea-Calvo Luis, Arteaga María J., Sanmartí Raimon, Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España, 10.1016/j.reuma.2014.05.002
10. Smolen Josef S, Breedveld Ferdinand C, Burmester Gerd R, Bykerk Vivian, Dougados Maxime, Emery Paul, Kvien Tore K, Navarro-Compán M Victoria, Oliver Susan, Schoels Monika, Scholte-Voshaar Marieke, Stamm Tanja, Stoffer Michaela, Takeuchi Tsutomu, Aletaha Daniel, Andreu Jose Louis, Aringer Martin, Bergman Martin, Betteridge Neil, Bijlsma Hans, Burkhardt Harald, Cardiel Mario, Combe Bernard, Durez Patrick, Fonseca Joao Eurico, Gibofsky Alan, Gomez-Reino Juan J, Graninger Winfried, Hannonen Pekka, Haraoui Boulos, Kouloumas Marios, Landewe Robert, Martin-Mola Emilio, Nash Peter, Ostergaard Mikkel, Östör Andrew, Richards Pam, Sokka-Isler Tuulikki, Thorne Carter, Tzioufas Athanasios G, van Vollenhoven Ronald, de Wit Martinus, van der Heijde Desirée, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force, 10.1136/annrheumdis-2015-207524
11. Putrik Polina, Ramiro Sofia, Keszei Andras P, Hmamouchi Ihsane, Dougados Maxime, Uhlig Till, Kvien Tore K, Boonen Annelies, Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study, 10.1136/annrheumdis-2014-206737
12. Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM, Sacnun MP, Soriano ER, Laurindo IM, Acevedo-Vásquez EM, Caballero-Uribe CV, Padilla O, Guibert-Toledano ZM, da Mota LM, Montufar RA, Lino-Pérez L, Díaz-Coto JF, Achurra-Castillo AF, Hernández JA, Esteva-Spinetti MH, Ramírez LA, Pineda C, Furst DE (2012) Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis Care Res (Hoboken) 64:1135–1143
13. Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, Hetland M L, Peets T, Immonen K, Maillefert J F, Drosos A A, Alten R, Pohl C, Rojkovich B, Bresnihan B, Minnock P, Cazzato M, Bombardieri S, Rexhepi S, Rexhepi M, Andersone D, Stropuviene S, Huisman M, Sierakowski S, Karateev D, Skakic V, Naranjo A, Baecklund E, Henrohn D, Gogus F, Badsha H, Mofti A, Taylor P, McClinton C, Yazici Y, Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database, 10.1136/ard.2009.109983

See also
	[boreal:220483]	Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.